Table 14 Characteristics of included studies- bladder cancer
From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Baris D [214], 2013, US | M/F | 2001–2004 | Population from Maine, Vermont and New Hampshire | 783 | 890 | Bladder cancer | Self-reported | Use at least 20 times(any) | 1,2,3,11,26,51 | 6 |
Fortuny J [215], 2007, US | M/F | 1998–2001 | The New Hampshire State Department of Health and Human Services’ rapid reporting Cancer Registry | 456 | 369 | Bladder cancer | Interview | Use at least four times a week for 1 month or longer prior to the reference date | 1,2,3,25 | 7 |
Fortuny J [216], 2006,Spain | M/F | 1997–2000 | Patients from five regions in Spain (Barcelona, Valle’s/Bages, Alacant, Tenerife, and Asturias) | 907 | 965 | Bladder cancer | Self-reported | Use twice or more weekly for ≥ 1 month (regular) | 1,2,3,25,26,52,53 | 8 |
Castelao JE [217], 2000, US | M/F | 1987–1996 | SEER cancer registry | 1514 | 1514 | Bladder cancer | Questionnaire | Use at least 20 times(any) | 3,5,53,54,55,56, 57,58,59,60 | 7 |
Steineck G [218], 1995, Sweden | M/F | 1985–1987 | Population from the County of Stockholm | 325 | 393 | Bladder cancer | Questionnaire | Had ever taken aspirin-not further defined | 1,2,3,55,56,61,62,63 | 5 |
Cohort studies | ||||||||||
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 175 | 142,330 | Bladder cancer | Questionnaire | Use at both baseline and year 3 visits (consistent) | 1,3,4,5,6,10,11,17,18,19,25,26,,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Shih C [219], 2013, US | M/F | 2000–2010 | The VITAL cohort | 344 | 77,048 | Bladder cancer | Questionnaire | Use at least once per week, for at least 1 year | 1,2,3,4,5,11,49 | 8 |
Daugherty SE [220], 2011, US | M/F | 1995–1996 | AARP | 1660 | 334,908 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 |
1993–2001 | PLCO Cancer Screening | 704 | 154,952 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 | ||
1994–1998 | The USRT Study | 97 | 90,972 | Bladder cancer | Questionnaire | Use aspirin ≥ 2times/week (regular) | 3,10,11,25,27 | 7 | ||
Genkinger JM [221], 2007, US | M | 1986–2004 | HPFS | 392 | 49,448 | Bladder cancer | Questionnaire | Use 2 or more times per week(regular) | 1,3,26,50 | 9 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 867 | 146,113 | Bladder cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,22, 25,45, 63 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population of North Jutland County | 161 | 29,470 | Bladder cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 35 | 12,668 | Bladder cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 96 | 13,870 | Bladder cancer | Questionnaire | Aspirin use: none,<daily, daily | 2 | 4 |